What to Be Aware of Before McKesson Corporation Announces Its Earnings

McKesson Corporation Prepares for Q3 2026 Earnings Announcement

McKesson Corporation (MCK), a leading healthcare services and IT provider headquartered in Irving, Texas, currently holds a market capitalization of $101.7 billion. The company specializes in the distribution of pharmaceuticals, medical equipment, and healthcare products, and also delivers advanced healthcare technology, practice management, and data analytics solutions. McKesson is set to release its financial results for the third quarter of fiscal 2026 after the market closes on Wednesday, February 4.

Analyst Expectations Ahead of Earnings

Analysts anticipate that McKesson will report earnings of $9.19 per share for the upcoming quarter, reflecting a 14.5% increase compared to $8.03 per share in the same period last year. The company has surpassed Wall Street’s earnings forecasts in three out of the last four quarters, with one quarter falling short. In the previous quarter, McKesson posted an EPS of $9.86, beating consensus estimates by 10.5%.

Future Earnings Projections

Looking ahead to the fiscal year ending March 2026, experts forecast that McKesson will achieve earnings of $38.61 per share, representing a 16.8% rise from $33.05 per share in fiscal 2025. For fiscal 2027, the company’s EPS is projected to climb 12.7% year-over-year to $43.53.

Image source: www.barchart.com

Stock Performance Overview

Over the past year, McKesson’s stock price has surged by 38%, significantly outpacing the S&P 500 Index’s 17% gain and the 12.6% increase posted by the State Street Health Care Select Sector SPDR ETF (XLV) during the same period.

Image source: www.barchart.com

Highlights from Recent Quarterly Results

On November 5, McKesson reported strong second-quarter results, which led to a 1.7% jump in its share price the following trading day. The company’s revenue grew by 10.1% year-over-year to $103.2 billion, driven by higher prescription volumes and greater distribution of oncology and multispecialty medications. Adjusted earnings per share reached $9.86, marking a 39.5% increase from the prior year’s quarter and surpassing analyst expectations by 10.5%.

Analyst Ratings and Price Targets

Wall Street remains bullish on McKesson’s prospects, assigning the stock an overall “Strong Buy” rating. Of the 17 analysts covering the company, 13 recommend “Strong Buy,” while four suggest holding the stock. The average price target stands at $940.94, implying a potential upside of 15.5% from current levels.